» Articles » PMID: 14718274

Skip Metastases in Thyroid Cancer Leaping the Central Lymph Node Compartment

Overview
Journal Arch Surg
Specialty General Surgery
Date 2004 Jan 14
PMID 14718274
Citations 76
Authors
Affiliations
Soon will be listed here.
Abstract

Hypothesis: Discontinuous nodal metastasis, or skip metastasis, in thyroid cancer may display clinicopathologic features different from those seen in continuous nodal metastasis and thus may have a different prognosis.

Design: Retrospective analysis.

Setting: Tertiary referral center at a university hospital.

Patients: Two hundred fifteen consecutive patients who underwent systematic central lymph node dissection for papillary, follicular, or medullary thyroid cancer and who on histopathologic analysis exhibited nodal metastases in at least 1 lateral or mediastinal lymph node compartment.

Main Outcome Measures: Various clinicopathologic variables that were stratified for tumor entity and type of nodal metastasis (discontinuous vs continuous).

Results: Skip metastases (negative central and positive lateral or mediastinal compartments) were found in 13 (19.7%) of 66 papillary, 0 of 8 follicular, and 30 (21.3%) of 141 medullary thyroid cancers. After adjustment for multiple testing, skip metastasis was only associated with significantly fewer positive lymph nodes: 3.7 vs 12.9 nodes (r = -0.43, P<.001) in papillary thyroid cancer and 6.0 vs 17.1 nodes (r = -0.40, P<.001) in medullary thyroid cancer. No other significant correlation was identified with any other clinicopathologic variable.

Conclusions: Skip metastasis is an epiphenomenon of low-intensity nodal metastasis in thyroid cancer and entails a moderate risk of local recurrence. Consequently, clearing the central lymph node compartment should be considered when lateral or mediastinal lymph node compartments are involved.

Citing Articles

The Value of Pretherapeutic Basal Calcitonin Cut-Offs for the Therapeutic Strategy and Prediction of Long-Term Outcome of Patients with Medullary Thyroid Cancer-A 30-Year Single-Center Experience.

Niederle M, Binter T, Riss P, Niederle B, Scheuba C Cancers (Basel). 2024; 16(19).

PMID: 39409963 PMC: 11482533. DOI: 10.3390/cancers16193343.


[30 years of prophylactic thyroidectomy for hereditary medullary thyroid cancer : A milestone in translational medicine].

Dralle H, Weber F, Lorenz K, Machens A Chirurgie (Heidelb). 2024; 95(8):638-650.

PMID: 38806713 PMC: 11286710. DOI: 10.1007/s00104-024-02105-x.


Latest Progress in Risk-Adapted Surgery for Medullary Thyroid Cancer.

Machens A, Lorenz K, Brandenburg T, Fuhrer D, Weber F, Dralle H Cancers (Basel). 2024; 16(5).

PMID: 38473279 PMC: 10930958. DOI: 10.3390/cancers16050917.


Surgical De-Escalation in Medullary Thyroid Cancer: A Commentary.

Ginzberg S, Krumeich L Oncologist. 2023; 28(12):1017-1019.

PMID: 37769340 PMC: 10712700. DOI: 10.1093/oncolo/oyad276.


Predicting skip metastasis in lateral lymph nodes of papillary thyroid carcinoma based on clinical and ultrasound features.

Zhao M, Shi X, Zou Z, Wen R, Lu Y, Li J Front Endocrinol (Lausanne). 2023; 14:1151505.

PMID: 37229457 PMC: 10203516. DOI: 10.3389/fendo.2023.1151505.